Cancer

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (NCT06662786)

Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis (NCT06603870)

• tsalvi@toh.ca

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer (NCT05849129)

• pwheatleyprice@toh.ca

Intensive Cancer Screening After Cryptogenic Stroke (NCT05733416)

• mdemetrof@ohri.ca

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters (NCT05029063)

• apecarskie@ohri.ca
• madhill@ohri.ca

Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD (NCT06016387)

Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis (NCT04671862)

• mgaudet@toh.ca
• krdennis@toh.ca

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial (NCT05955924)

• clennox@ohri.ca

A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver (NCT05677113)

• roleclerc@ohri.ca

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (NCT06586515)

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy (NCT05169112)

• rbreau@ottawahospital.on.ca
• pjuneau@ohri.ca

The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III (NCT04871412)

• afazekas@toh.ca

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (NCT06131840)

Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) (NCT04574960)

• pjuneau@ohri.ca

The DRAGON 2 Trial (NCT05428735)

Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) (NCT04874038)

Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) (NCT04448184)

• atinmouth@ohri.ca

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge (NCT04335292)

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis (NCT02869802)

Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis (NCT06894576)

• hlanglois@ohri.ca

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy (NCT05920343)

• lulavallee@toh.ca
• dyachnin@toh.ca

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) (NCT06462183)

A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing (NCT06129084)

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (NCT06345079)

• rgoodwin@toh.ca

IBD Neoplasia Surveillance RCT (NCT05809999)

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer (NCT05601440)

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors (NCT06157892)

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (NCT05696626)

• rgoel@ottawahospital.on.ca

Met Non Small Cell Cancer Registry (MOMENT) (NCT05376891)

• pwheatleyprice@toh.ca

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction (NCT04680442)

• kelross@ohri.ca

Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC (NCT04093167)

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE (NCT05171075)

Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism (NCT04304651)

• adelluc@toh.ca
• mcarrier@toh.ca

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies (NCT03847649)

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596)

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) (NCT04151342)

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606)

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors (NCT06532565)

Dose Escalation For INtraprostatic LEsions (NCT05851547)

• sgrimes@ohri.ca

Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial (NCT05820126)

• amclement@ohri.ca

SNV4818 in Participants With Advanced Solid Tumors (NCT06736704)

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (NCT03127631)

• dyachnin@toh.ca

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies (NCT06208735)

• vlopez@ohri.ca

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy (NCT05753618)

• lvandermeer@ohri.ca

International Registry for Men With Advanced Prostate Cancer (IRONMAN) (NCT03151629)

A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors (NCT06384352)

• junakamura@ohri.ca

SpaceIT Hydrogel System for Perirectal Spacing (NCT06451614)

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (NCT06618287)

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer (NCT02468024)

• sgilbert@toh.ca
• afazekas@toh.ca

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy (NCT04928261)

• lvandermeer@ohri.ca

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (NCT06790693)

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)

TRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence (NCT04874064)

• natremblay@ohri.ca

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer (NCT06435429)

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (NCT05789082)

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (NCT04812366)

• pjuneau@ohri.ca

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05581004)

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (NCT05464030)

A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (NCT05538130)

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (NCT05355701)

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (NCT05379595)

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802)

• djonker@toh.ca

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) (NCT05384626)

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (NCT03765177)

• nkekre@toh.on.ca
• vlopez@ohri.ca

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours (NCT04421820)

• saali@ohri.ca
• roleclerc@ohri.ca

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (NCT06136624)

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (NCT05253651)

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss (NCT04065269)

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (NCT04895709)

PSMA-PET Registry for Recurrent Prostate Cancer (NCT03718260)

• dyachnin@ohri.ca

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (NCT04728893)

Study Looking at Biomarkers in Ovarian Cancer (NCT03419689)

• jweberpals@toh.ca

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (NCT04589845)

A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test (NCT04529122)

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer (NCT04486378)

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (NCT02906943)

• hanzhang@ohri.ca
• kchristink@toh.ca

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (NCT06592924)

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (NCT06428409)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (NCT06393374)

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer (NCT06205485)

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (NCT05773274)

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (NCT06136650)

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study (NCT05987241)

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer (NCT05946213)

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab (NCT05812807)

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer (NCT05624996)

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT05445778)

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (NCT05174169)

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer (NCT04340141)

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (NCT03488693)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (NCT03486873)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry (NCT05430971)